Continuing war on pain: a personalized approach to the therapy with nonsteroidal anti-inflammatory drugs and opioids

Continuing war on pain: a personalized approach to the therapy with nonsteroidal anti-inflammatory drugs and opioids

Successful pain management requires the delivery of analgesia with minimal risk of adverse drug reactions. Nonsteroidal anti-inflammatory drugs and opioids remain the mainstay of treatment for the majority of patients. Unfortunately, almost 50% of all patients experience inadequate pain relief and s...

Full description

Saved in:
Bibliographic Details
Published in:Personalized medicine Vol. 16; no. 2; p. 171
Main Authors: Bach-Rojecky, Lidija, Vađunec, Dalia, Žunić, Katarina, Kurija, Jelena, Šipicki, Sara, Gregg, Ryan, Mikula, Ivan, Primorac, Dragan
Format: Journal Article
Language:English
Published: England 01-03-2019
Subjects:
Analgesics - pharmacology
Analgesics, Opioid - pharmacology
Anti-Inflammatory Agents, Non-Steroidal - pharmacology
Humans
Pain - drug therapy
Pain - physiopathology
Pain Management - methods
Pain Management - trends
Pharmacogenomic Testing
Pharmacogenomic Variants
Precision Medicine - methods
nonsteroidal anti-inflammatory drugs
toxicity
genes
analgesic effect
pain treatment
side effects
epigenetics
pharmacogenetics
opioids
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Successful pain management requires the delivery of analgesia with minimal risk of adverse drug reactions. Nonsteroidal anti-inflammatory drugs and opioids remain the mainstay of treatment for the majority of patients. Unfortunately, almost 50% of all patients experience inadequate pain relief and serious side effects. Allelic variants in genes coding for target proteins, transporters and enzymes, which govern analgesic drugs action and their fate in the organism, might explain inter-individual variability in pain severity and in drug-induced pain relief and toxicities. Additionally, it seems that epigenetic changes contribute to the highly variable response to pain treatment. Therefore, pharmacogenomic testing might be a valuable tool for personalization of pain treatment, with a multidisciplinary team approach involved.
ISSN:1741-0541
DOI:10.2217/pme-2018-0116